Format

Send to

Choose Destination
Am J Geriatr Psychiatry. 2015 May;23(5):506-13. doi: 10.1016/j.jagp.2014.06.008. Epub 2014 Jun 26.

Comparing engage with PST in late-life major depression: a preliminary report.

Author information

1
Weill Cornell Institute of Geriatric Psychiatry, White Plains, NY. Electronic address: gsalexop@med.cornell.edu.
2
Weill Cornell Institute of Geriatric Psychiatry, White Plains, NY.
3
Department of Psychiatry, University of California, San Francisco, CA.

Abstract

OBJECTIVE:

The complexity of psychotherapies has been a barrier to community implementation. We used the Research Domain Criteria consensus as a guide to develop Engage, a streamlined, neurobiology-based psychotherapy for late-life depression that may match the skill set of practicing clinicians. This proof of concept study tested the hypotheses that Engage is bioequivalent to Problem Solving Therapy (PST) in reducing depressive symptoms, inducing remission, and ameliorating disability.

METHODS:

Engage assumes that abnormal function of the positive valence systems fuels depression and uses "reward exposure" (engagement in meaningful, rewarding activities) as its principal intervention. Negativity bias, apathy, and emotional dysregulation are expressions of abnormalities in the negative valence, arousal and regulatory, and cognitive control systems, respectively. Engage targets each of them with simple interventions only if they interfere with reward exposure. We treated openly, with 9 weekly sessions of Engage, 39 older adults with unipolar major depression. We compared their course of depression (HAM-D), remission rate (HAM-D<10), and disability (WHODAS) with those of a historical comparison group (N = 97) treated with 9 weekly sessions of PST.

RESULTS:

Community social workers and research therapists required one third as much training time in Engage as in PST. Engage was non-inferior to PST in reducing HAM-D and WHODAS. Remission rates for Engage at 6 and 9 weeks were 18.2% and 41.1%, respectively. The corresponding figures for PST were 13.7% and 35.0%, respectively.

CONCLUSION:

These initial observations suggest that Engage has comparable efficacy with PST in reducing depressive symptoms and disability and warrants a randomized controlled trial.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00052091 NCT01698255.

KEYWORDS:

Late-life depression; RDoC consensus; neurobiology-based; psychotherapy

PMID:
25081818
PMCID:
PMC4277491
DOI:
10.1016/j.jagp.2014.06.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center